Document ID: chunk:federal_register_of_legislation:F2018L00192:reg:9:p1
Version: federal_register_of_legislation:F2018L00192
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3357–6332

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting toxic retinopathy or death from toxic retinopathy with the circumstances of a person's relevant service:
(1)          being treated with a quinoline-based drug as specified, before the clinical onset of toxic retinopathy;
Note: being treated with a quinoline-based drug as specified is defined in the Schedule 1 - Dictionary.
(2)          being treated with tamoxifen as specified within the one year before the clinical onset of toxic retinopathy;
Note: being treated with tamoxifen as specified is defined in the Schedule 1 - Dictionary.
(3)          being treated with an intravitreal or subconjunctival aminoglycoside from the specified list of aminoglycosides, within the seven days before the clinical onset of toxic retinopathy;
Note: specified list of aminoglycosides is defined in the Schedule 1 - Dictionary.
(4)          being treated with intravitreal fomivirsen or ganciclovir within the 30 days before the clinical onset of toxic retinopathy;
(5)          being treated with intravenous deferoxamine within the seven days before the clinical onset of toxic retinopathy;
(6)          being treated with a phenothiazine from the specified list of phenothiazines for a continuous period of at least the two weeks before the clinical onset of toxic retinopathy;
Note: specified list of phenothiazines is defined in the Schedule 1 - Dictionary.
(7)          being treated with daily clofazimine, at an average dose of at least 100 milligrams per day, for a continuous period of at least the three months before the clinical onset of toxic retinopathy;
(8)          being treated with ritonavir for a continuous period of at least the three months before the clinical onset of toxic retinopathy;
(9)          being treated with interferon for a continuous period of at least four weeks, within the three months before the clinical onset of toxic retinopathy;
(10)      being treated with daily topiramate for a continuous period of at least seven days within the 30 days before the clinical onset of toxic retinopathy;
(11)      having iron chelating therapy as specified for a continuous period of at least the four weeks before the clinical onset of toxic retinopathy;
Note: iron chelating therapy as specified is defined in the Schedule 1 - Dictionary.
(12)      having haematological or biochemical evidence of poisoning with cobalt at the time of the clinical onset of toxic retinopathy;
(13)      taking oral canthaxanthin supplements or tablets as specified within the five years before the clinical onset of toxic retinopathy;
Note: taking oral canthaxanthin supplements or tablets as specified is defined in the Schedule 1 - Dictionary.
(14)      inhaling isopropyl nitrite within the two weeks before the clinical onset of toxic retinopathy;
(15)      using an intravenous drug